Drugs / SPK-10001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06826612 | Feb 2025 → Jan 2035 expected | Huntington disease | Hoffmann-La Roche | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPK-10001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06826612 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “SPK-10001 Gene Therapy” NCT06826612 ↗ |
| Route | Other | “Intraparenchymal Infusion of SPK-10001 Into the Caudate and Putamen” NCT06826612 ↗ |